ClinicalTrials.Veeva

Menu
C

Central States Research | Tulsa, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Troriluzole
Donanemab
Metformin
Retatrutide
Gantenerumab
Orforglipron
Cannabidiol
BI 1358894
Lecanemab
Nicotine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 32 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two d...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN00...

Enrolling
Fragile X Syndrome
Drug: Placebo
Drug: ZYN002 - transdermal gel
Locations recently updated

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Enrolling
Type 2 Diabetes
Drug: Retatrutide
Drug: Placebo
Locations recently updated

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Enrolling
Diabetes Mellitus, Type 2
Drug: Retatrutide
Drug: Semaglutide

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery)....

Invitation-only
Fragile X Syndrome
Drug: ZYN002 - Cannabidiol Transdermal Gel

Trial sponsors

Lilly logo
AbbVie logo
Roche logo
University of Southern California logo
Z
Biohaven logo
Novo Nordisk logo
Acadia Pharmaceuticals logo
AnaptysBio logo
Biogen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems